The Healthcare sector is made up of devices and systems that support healthcare organizations such as hospitals, doctor’s offices, surgical centers, and more. Healthcare technologies range from equipment like imaging machinery and robotic surgical assistants to patient recordkeeping applications and scheduling support. Register today to discover how Forge can help you buy and sell private shares.
Register to add companies to your watchlist and get access to bids/asks activity, last matched price and trade eligibility details.
Register| Active Market | Forge Price1 | Last Funding Round | Trade Eligibility | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Company | Sector & Subsector | Market Activity4 |
Highest Bid | Lowest Ask | Last Matched | +/- to LFR | $ Total Bids | $ Total Asks | # Bids | # Asks | Current Price |
6-month |
1-year |
Total Funding |
Round | Date | Amount Raised |
Post-Money Valuation3 |
Price |
Key Investors | Common | Preferred | Fund | ||
| Evommune | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $268.46MM | Series C | 10/31/2024 | $115.5MM | $346.35MM | $1.59 | RA Capital Management, Sectoral Asset Management, B Capital, Marshall Wace, Avego Bioscience Capital, Longwood Fund, RTW Investments, ADAR1 Capital Management, NEXTBio Capital, Beiersdorf Venture Capital, FemHealth Ventures, Allostery Investments LP, Pivotal bioVenture Partners, EQT Life Sciences, Andera Partners, Amplitude Ventures, SymBiosis, Verition Fund Management | |||||
| Homeward Health | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $70MM | Series B | 8/3/2022 | $50MM | $345.14MM | $12.85 | ARCH Venture Partners, Human Capital, General Catalyst, 7wireVentures | |||||
| Apexigen | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $165.38MM | Series C | 3/24/2020 | $127.86MM | $343.82MM | $1.55 | Decheng Capital, Oceanpine Capital, 3E Bioventures Capital, VI Ventures, SV Tech Ventures, H&Q Asia Pacific, LDV Ventures, ShangBay Capital, Delian Capital, Hua Nan Venture Capital, Efung Capital | |||||
| Aerin Medical | Healthcare Medical Devices | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $172.7MM | Series G | 1/13/2025 | $32.82MM | $342.42MM | $1.17 | KCK MedTech, Questa Capital, OrbiMed, Ally Bridge Group, Ares Capital | |||||
| SmarterDx | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $70.97MM | Series B | 5/14/2024 | $50MM | $341.85MM | $16.75 | Transformation Capital, Bessemer Venture Partners, Flare Capital Partners, Floodgate | |||||
| Florence | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $243.44MM | Series C-1A | 6/22/2022 | $10.64MM | $339.88MM | $11.02 | Insight Partners | |||||
| Aspen Neuroscience | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $339.74MM | Series C | 11/20/2025 | $115.62MM | $339.66MM | $1.52 | OrbiMed, ARCH Venture Partners, Frazier Healthcare Partners, Revelation Partners, Medical Excellence Capital, S32, Axon Ventures, LYFE Capital, LifeForce Capital, Kite, Balyasny Asset Management, Cormorant Asset Management, Prebys Ventures | |||||
| Linus Health | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $129.55MM | Series B-1 | 7/6/2021 | $43.94MM | $339.45MM | $4.93 | Morningside Ventures | |||||
| Cresilon | Healthcare Medical Devices | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $126.97MM | Series A-5 | 4/11/2025 | $41.25MM | $338.51MM | $2.04 | Undisclosed Investors | |||||
| Hexagon Bio | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $194.66MM | Series B | 2/13/2023 | $77.3MM | $338.5MM | $4.23 | The Column Group, Two Sigma Ventures, 8VC, Nextech Invest, CPP Investments, ATEL Ventures | |||||
| AgNovos Bioscience | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $257.83MM | Series B | 12/20/2023 | $44.85MM | $338.24MM | $35.76 | Undisclosed Investors | |||||
| Atsena Therapeutics | Healthcare Other Healthcare | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $235.9MM | Series C-3 | 4/2/2025 | $60MM | $337.46MM | $4.13 | Bain Capital, Wellington Management, Lightstone Ventures, Sofinnova Investments, Abingworth, Foundation Fighting Blindness, Hatteras Venture Partners, Osage University Partners, Manning Family Foundation | |||||
| PineTree Therapeutics | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $87.5MM | Series B | 10/28/2025 | $47MM | $336.28MM | $12.00 | DSC Investment, WIDWIN Investment, STIC Ventures, Samho Green Investment, Atinum Investment, S&S Investment, SJ Investment Partners, Smilegate Investment, Gauss Capital Management, Korea Investment Partners, SV Investment | |||||
| Emerald Cloud Lab | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $151.12MM | New Series C-1 | 7/25/2025 | $65MM | $335.94MM | $0.51 | Undisclosed Investors | |||||
| NowRx | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $114.11MM | Series C | 10/7/2021 | $74.03MM | $334.19MM | $10.50 | Undisclosed Investors | |||||
| Vanqua Bio | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $149.15MM | Series B | 7/12/2024 | $130MM | $333.4MM | $4.06 | Omega Funds, OrbiMed, Citadel, Avoro Ventures, Casdin Capital, Pontifax, Eli Lilly and Company, Logos Capital, Osage University Partners | |||||
| CytoVale | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $204.3MM | Series D | 10/10/2024 | $101MM | $333.35MM | $2.77 | Sands Capital, CPP Investments, Norwest Venture Partners, Global Health Investment Corporation, Breakout Ventures, Alumni Ventures | |||||
| ShapeTX | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $249.61MM | Series C-1 | 1/7/2025 | $91.03MM | $333.34MM | $0.41 | Undisclosed Investors | |||||
| Egenesis | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $1.4B | Series D | 9/4/2024 | $90.96MM | $332.59MM | $0.20 | Lux Capital, ARCH Venture Partners, Khosla Ventures, Farallon Capital Management, Alta Partners, Fresenius Medical Care Ventures, Leaps by Bayer, DaVita, Eisai Innovation, NATCO Pharmaceuticals, Parkwood Corporation | |||||
| Neuron23 | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $310.11MM | Series D | 6/24/2025 | $96.5MM | $331.2MM | $0.99 | Westlake Village BioPartners, SoftBank, Redmile Group, Blue Owl, Kleiner Perkins, HBM Healthcare Investments, Acorn Bioventures | |||||
| AIRNA | Healthcare Medical Devices | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $245.25MM | Series B | 4/1/2025 | $155MM | $330.71MM | $0.93 | Venrock, Forbion, RTW Investments, Nextech Invest, ARCH Venture Partners, ND Capital | |||||
| Brightside | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $122.97MM | Series C-2 | 7/28/2025 | $4.62MM | $330.23MM | $9.39 | Undisclosed Investors | |||||
| ClevelandDx | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $117.45MM | Series E-2 | 10/7/2025 | $26.99MM | $330.17MM | $4.99 | Novo Holdings | |||||
| Ceribell | Healthcare Medical Devices | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $153.6MM | Series C-1 | 9/22/2022 | $100.39MM | $328.64MM | $11.49 | Longitude Capital, The Rise Fund, RA Capital Management, Redmile Group, Red Tree Venture Capital, Ally Bridge Group | |||||
PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES
Forge Price™ is a custom data-point calculated and disseminated by Forge Data LLC (“Forge Data”) and is a mark of Forge Data. Forge Price may rely on a very limited number of inputs in its calculation. Forge Price is prepared and disseminated solely for informational purposes. Redistribution is permitted solely with Forge’s written consent. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of Forge Price, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of Forge Price. Forge Price is derived from secondary activity on the Forge platform and other private market trading platforms, and other publicly-available datapoints collected by Forge. Forge Price is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Neither reference to company names, nor calculation of Forge Price for a specific company, implies any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company. The dollar-figure and percentage displayed indicates the per share change in dollar amount and percentage since the most recent Forge Price change. Percentages are rounded to the nearest whole number.
The dollar-figure and percentage displayed indicates the per share change in dollar amount and percentage since the most recent Forge Price change. Percentages are rounded to the nearest whole number.
Post-Money Valuation (valuation) represents the estimated valuation based on company-submitted Certificates of Incorporations (COIs).
Market activity indicates the level of activity for a company based on recent IOIs, secondary transactions, and pending transactions.
Sector and subsector descriptions focus primarily on the types of companies within the respective sectors and subsectors that are typically available through Forge Markets. Any sector or subsector as a whole may include companies that participate in business lines in other sectors or subsectors. Companies are classified into sectors and subsectors according to the problem(s) they seek to solve rather than the method by which the solution is delivered.